May have altered solubility & reduced bioavailability w/ PPIs, H2
-receptor antagonists & antacids. May have increased systemic exposure w/ inhibitors of P-gp (eg, clarithromycin, erythromycin, azithromycin, verapamil, cyclosporin), CYP2C9 (amiodarone, fluconazole or miconazole) or CYP3A4 (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin or voriconazole). May have decreased exposure w/ CYP inducers (rifampicin, carbamazepine, phenytoin, St. John's wort). May give rise to increased exposure of medicinal products transported by breast cancer resistance protein eg, rosuvastatin, topotecan & sulfasalazin. Caution w/ contraceptive steroids.